問卷

TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Thoracic Medicine

Division of General Internal Medicine

Division of Hematology & Oncology

更新時間:2023-09-19

廖信閔Liao, Xin-Min
  • Principal Investigator
  • Clinical Trial Experience (year) 12 years 9 個月

篩選

List

1Cases

2020-04-01 - 2025-11-26

Phase III

Completed
A Phase 3, Randomized, Open Label Study to Compare Nivolumab Plus Concurrent Chemoradiotherapy (CCRT) Followed by Nivolumab Plus Ipilimumab or Nivolumab Plus CCRT Followed by Nivolumab vs CCRT Followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)
  • Condition/Disease

    Previously Untreated, Locally Advanced Non-small Cell Lung Cancer

  • Test Drug

    OPDIVO (nivolumab) Injection 10mg/mL OPDIVO (nivolumab) Injection 10mg/mL YERVOY (ipilimumab) Injection 5mg/mL YERVOY (ipilimumab) Injection 5mg/mL

Participate Sites
7Sites

Not yet recruiting1Sites

Recruiting6Sites